Hans-Georg Kopp - JoVE Visualize

Showing results (81-90 of 98) with videos related to

Pageof 10

Sort By:

Nature Communications|December 2, 2021

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancerClemens Hinterleitner, Jasmin Strähle, Elke Malenke, et al.

Acta Neuropathologica|August 25, 2011

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.

Lung Cancer (Amsterdam, Netherlands)|August 8, 2025

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.

European Journal of Cancer (Oxford, England : 1990)|January 25, 2024

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.

International Journal of Cancer|April 28, 2020

Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.

Nature Medicine|May 2, 2006

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytesDavid K Jin, Koji Shido, Hans-Georg Kopp, et al.

European Journal of Cancer (Oxford, England : 1990)|December 10, 2022

Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approachesCristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.

JAMA Surgery|April 3, 2020

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.

International Journal of Cancer|August 29, 2024

Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)Christina Schulte, Thomas Gauler, Christoph Pöttgen, et al.

Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:

Pageof 10

Nature Communications|December 2, 2021

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancerClemens Hinterleitner, Jasmin Strähle, Elke Malenke, et al.

Acta Neuropathologica|August 25, 2011

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor VorinostatTill Milde, Susanne Kleber, Andrey Korshunov, et al.

Lung Cancer (Amsterdam, Netherlands)|August 8, 2025

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.

European Journal of Cancer (Oxford, England : 1990)|January 25, 2024

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.

International Journal of Cancer|April 28, 2020

Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.

Nature Medicine|May 2, 2006

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytesDavid K Jin, Koji Shido, Hans-Georg Kopp, et al.

European Journal of Cancer (Oxford, England : 1990)|December 10, 2022

Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approachesCristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.

JAMA Surgery|April 3, 2020

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.

International Journal of Cancer|August 29, 2024

Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)Christina Schulte, Thomas Gauler, Christoph Pöttgen, et al.

Pageof 10